Pearson, Sallie-Anne

Effect of salt substitution on cardiovascular events and death

Neal, B., Wu, Y., Feng, X., Zhang, R., Zhang, Y., Shi, J., Zhang, J., Tian, M., Huang, L., Li, Z., et al. (2021) · New England Journal of Medicine

Sodium Intake and HealthBlood Pressure and Hypertension Studies

Cited by 742

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Neuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 358

Computerized clinical decision support for prescribing: provision does not guarantee uptake

Moxey, A., Robertson, J., Newby, D., Hains, I., Williamson, M., & Pearson, S.-A. (2010) · Journal of the American Medical Informatics Association

Electronic Health Records SystemsArtificial Intelligence in Healthcare and Education

Cited by 305

Do computerised clinical decision support systems for prescribing change practice? A systematic review of the literature (1990-2007)

Pearson, S.-A., Moxey, A., Robertson, J., Hains, I., Williamson, M., Reeve, J., & Newby, D. (2009) · BMC Health Services Research

Electronic Health Records SystemsPharmaceutical Practices and Patient Outcomes

Cited by 193

Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review

Parkinson, B., Sermet, C., Clement, F., Crausaz, S., Godman, B., Garner, S., Choudhury, M., Pearson, S.-A., Viney, R., Lopert, R., et al. (2015) · PharmacoEconomics

Pharmaceutical Economics and PolicyHealth Systems, Economic Evaluations, Quality of Life

Cited by 93

Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)

Lin, J., Pearson, S.-A., Greenfield, J. R., Park, K. H., Havard, A., Brieger, D., Day, R. O., Falster, M. O., & de Oliveira Costa, J. (2023) · European Journal of Clinical Pharmacology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 48

Racial Disparities in Access After Regulatory Surveillance of Benzodiazepines

Pearson, S.-A., Soumerai, S., Mah, C., Zhang, F., Simoni-Wastila, L., Salzman, C., Cosler, L. E., Fanning, T., Gallagher, P., & Ross-Degnan, D. (2006) · Archives of Internal Medicine

Opioid Use Disorder TreatmentPharmaceutical Practices and Patient Outcomes

Cited by 34

A cross sectional study of psychotropic medicine use in Australia in 2018: a focus on polypharmacy

Brett, J., Pearson, S., Daniels, B., Wylie, C. E., & Buckley, N. A. (2021) · British Journal of Clinical Pharmacology

Pharmaceutical Practices and Patient OutcomesMental Health Treatment and Access

Cited by 18